|Bid||83.93 x 1000|
|Ask||83.95 x 800|
|Day's Range||83.70 - 85.10|
|52 Week Range||64.38 - 101.17|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.69|
|Expense Ratio (net)||0.35%|
The SPDR S&P Biotech ETF (XBI) , which rallied earlier this week amid some deal-making in the sector, is up 7.70% this month and some market observers believe biotechnology stock can extend their recent bullishness. XBI one of the largest biotechnology exchange traded funds (ETFs), has a rich history of delivering summer upside. Healthcare stocks are also showing attractive valuations relative to other defensive sectors, which are richly valued.
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
Market players are standing aside while they await the Fed's interest rate decision on Wednesday afternoon. Despite the lethargic action, some positive movement came in biotechnology, because of the takeover action in the sector. exchange-traded fund had a very solid gain of 4.7%.
Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting ...
If you read my update last week, you know that we were looking for a possible resumption of the $SPX cash on a pullback to the December lows. Although the first key support was violated on the way down, the second general zone held up and was followed with a 30-minute buy trigger that is described in the trigger video, below.
The summer months can be unkind to the broader market, but some sector and industry funds perform well as temperatures heat up. The SPDR S&P Biotech ETF (XBI) , one of the largest biotechnology exchange traded funds (ETFs), has a rich history of delivering summer upside. Healthcare stocks are also showing attractive valuations relative to other defensive sectors, which are richly valued.
The FDA's latest guidelines outlined the studies a company making a biosimilar — a copycat version of the pricey biologic — should conduct to obtain the interchangeable designation. A biologic can cost up to hundreds or thousands of dollars for some chronic conditions. "This guidance is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is interchangeable with a reference product for the purposes of submitting a marketing application or supplement," the FDA said.
While we can research the family tree for these health issues, it’s been difficult to know for sure what could happen — until now. Because of breakthroughs in human genome mapping, we can now get a clear line of sight on what diseases are coming our way — and the insights are only getting better.
With sector weakness since early April shaving 8%-10% off the iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) for example, potential takeover targets in fact are now more attractive. Large pharma and biotech companies need to build out their product pipelines, and many have the buying power to make acquisitions. "The appetite for M&A is still high," says Jared Holz, of the healthcare sector trading desk at Jefferies.
Biotech stocks bucked the broader market uptrend in April, thanks to the volatility associated with the sector. Some of the catalysts that drove stocks include clinical trial readouts, capital raising ...
Gilead investors have had their patience tried lately. While the company’s peers tracked by the (XBI) and the (IBB) (IBB) have enjoyed double-digit gains year to date, along with the broader market, Gilead stock is up an anemic 4.2% since the start of the year. Gilead still earns plenty of analyst praise, and new leadership has sparked some enthusiasm.
Biotech was particularly hit hard as "Medicare for All" and other possible government intervention across the industry received more attention as we get deeper in the 2020 election cycle. Unfortunately, algorithmic trading has become part of life in the market in recent years. On any given day up to 80% of the market's overall trading volume can be driven by computer-generated program trading.
The SPDR S&P Biotech ETF (XBI) , one of the largest biotechnology exchange traded funds (ETFs), is up more than 24% this year, indicating the biotech space remains in favor as investors look for avenues to access innovative concepts and themes. Healthcare stocks are also showing attractive valuations relative to other defensive sectors, which are richly valued. Biotechnology historically trades at multiples that are elevated relative to broader benchmarks, but after last year’s of struggles for biotechnology names, some analysts see value with some big-name biotech stocks.
Healthcare stocks and sector-related exchange traded funds took a heavy blow Wednesday, trailing the broader market by a historic margin early in 2019, as political risks on Capitol Hill ramped up. The sector's latest drop has been attributed to a number of signs that politicians on both sides of the aisle in Congress are eyeing tighter regulations ahead of the 2020 presidential election, the Wall Street Journal reports. Insurers have also taken the brunt of the hit and was among the market's worst performers in recent trading amid uncertainty over the future of the U.S. healthcare policy, with UnitedHealth on pace for its worst month in a decade as the "Medicare for All" mantra weighs on investment confidence.
For exchange-traded fund (ETF) investors, the SPDR S&P 500 ETF (SPY) has been a dietary staple for many years. After posting $4.1 billion of outflows during the first quarter, SPY, the largest ETF that tracks the S&P 500, attracted more than $5.3 billion of inflows to start the second quarter. "It's the bellwether of all ETFs," said ETF Trends CEO Tom Lydon. "Because it's the biggest, the spreads between the bid and the ask are really, really tight," said Lydon.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.